03:47 AM EST, 11/19/2025 (MT Newswires) -- Viking Therapeutics ( VKTX ) said Wednesday it finished enrolling patients in its phase 3 Vanquish 1 study of a once-weekly subcutaneous drug for adults with obesity.

The randomized, double blind, placebo-controlled trial will treat participants for 78 weeks and includes about 4,650 adults who are obese or overweight with at least one weight-related condition, the company said.

Patients were assigned to weekly doses of 7.5 milligrams, 12.5 milligrams, or 17.5 milligrams, or placebo, with the primary endpoint to measure percent change in body weight at week 78 and a 52-week extension for continued treatment, Viking said.

Secondary and exploratory measures include the share of participants reaching at least 5%, 10%, 15% and 20% weight loss along with other safety and efficacy outcomes, it said.

Viking is also running the phase 3 Vanquish 2 study of the same drug in people with type 2 diabetes who have obesity or are overweight and aims to complete enrollment in that trial in Q1 2026, it said.